Abstract: This disclosure relates to medical fluid sensors and related systems and methods. In certain aspects, a method includes using a medical fluid pump of a medical fluid pumping machine, such as a hemodialysis machine, to deliver medical fluid to a first portion of a cartridge that is positioned within a magnetic field, exciting atoms in the medical fluid in the first portion of the cartridge by applying radio frequency energy to the medical fluid in the first portion of the cartridge, receiving radio frequency energy generated by the excited atoms in the medical fluid in the first portion of the cartridge, and determining a concentration of a substance in the medical fluid based on the received radio frequency energy generated by the excited atoms in the medical fluid in the first portion of the cartridge.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A and A? are independently C or N, where C may be unsubstituted or substituted by halo or C1-C6 alkyl; R and R0 are independently selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), and —(CH2)n—W, where W is C3-C8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1-3 N, S and/or O atoms, —SO2—R?, —NHSO2—R?, —NR?SO2—R? and SR?, where R? and R? are independently C1-C6 alkyl or C3-C8 cycloalkyl, etc.; wherein each of said alkyl, cycloalkyl, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, heteroaryl, etc.

Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: This disclosure relates to medical fluid sensors and related systems and methods. In certain aspects, a method includes reading an indicia of a medical fluid cartridge to determine a volume of a fluid passageway of the medical fluid cartridge indicated by the indicia, receiving radio frequency energy generated by excited atoms in medical fluid in the fluid passageway of the medical fluid cartridge, and determining a concentration of a substance in the medical fluid based on the determined volume of the fluid passageway of the medical fluid cartridge indicated by the indicia and the received radio frequency energy generated by the excited atoms in the medical fluid in the fluid passageway of the medical fluid cartridge.

Abstract: A photodynamic therapy lamp includes two lamp modules comprising an array of LEDs. Each of the lamp modules is movable between a first position in which an angle between the lamp modules is from 157 degrees to 180 degrees, and a second position in which the angle between the lamp modules is from 50 degrees to 70 degrees.

Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt or solvate thereof, wherein A and A? are C or N, where C may be substituted by halo or C1-C6 alkyl; R and R0 are selected from the group consisting of H, C1-C6 alkyl, —(CH2)n—W, etc., where W is 5- or 6-membered heteroaryl or heterocyclic containing N, S and/or O atoms, —NR?SO2—R?, etc., where R? and R? are C1-C6 alkyl, etc.; wherein each alkyl, etc., may be substituted; or, R and R0 and the N atom to which they are bonded together to form a monocyclic or bicyclic heterocyclic ring, etc.; R1 is H, halo or cyano; R2 and R2? are H, C1-C6 alkyl, etc.; X is a bond, etc.; R3 is H, C1-C4 alkyl, etc.; Y is a bond, —(CH2)m—, etc. The invention also relates to compositions and uses in the treatment of various diseases.

Abstract: A cam rocker lever comprises an annular piece with an inner diameter, a cam lobe, a first linear portion, and a second linear portion. The cam lobe is disposed within the inner diameter of the annular piece. The first linear portion extends from a first side of the annular piece, and a second linear portion extends from a second side of the annular piece opposite the first side. The first linear portion is configured to connect to a stem of a valve such that the valve is displaced when the first linear portion is displaced.

Abstract: An electronic management system comprising of digital processors, database storage medium and input and output devices; said system executing software steps in the management of transactions between financial entities; said financial entities including at least an owner/s of a property, a retirement fund of said owner/s and an associated managed fund; said transactions including application by said owner/s for an acquisition by said managed fund of investment equity in said owner/s' property. Also described is a digital input/output device incorporating means to recognise a physiological feature of a prospective member preparatory to comparing that physiological feature with a database of physiological features for verification of the identity of the member thereby to permit access by the member to the system described above.

Abstract: This disclosure relates to medical fluid sensors and related systems and methods. In some aspects, a medical fluid cartridge includes a body including a first portion defining a first fluid passageway and a second portion defining a second fluid passageway in fluid communication with the first fluid passageway. The body defines a gap between the first portion of the body and the second portion of the body such that the first portion of the body can be disposed in a radio frequency device while the second portion of the body remains outside the radio frequency device.

Abstract: A movable platform has a front end, a back end, a longitudinal axis, and at least one axle oriented generally transverse to the longitudinal axis and located between the front and back ends for supporting wheels of the platform. A position sensor is affixed on the platform at a location other than at a location defined by a plane passing through the axle and normal to the longitudinal axis. The position sensor provides position data as the platform traverses a path. A sensor arrangement is supported by the platform and configured to provide subsurface sensor data as the platform traverses the path. A processor is configured to associate the position data with the sensor data relative to a reference frame and in a manner that accounts for dynamic motion of the platform.

Abstract: This disclosure relates to medical fluid sensors and related systems and methods. In some aspects, a medical fluid cartridge includes a body including a first portion defining a first fluid passageway and a second portion defining a second fluid passageway in fluid communication with the first fluid passageway. The body defines a gap between the first portion of the body and the second portion of the body such that the first portion of the body can be disposed in a radio frequency device while the second portion of the body remains outside the radio frequency device.

Abstract: A photodynamic therapy lamp includes two lamp modules comprising an array of LEDs. Each of the lamp modules is movable between a first position in which an angle between the lamp modules is from 157 degrees to 180 degrees, and a second position in which the angle between the lamp modules is from 50 degrees to 70 degrees.

Abstract: A connectivity device, such as a switch may consume lesser power by transitioning into stand-by mode in response to a command from an upstream connectivity device, such as another switch. In the stand-by mode the switch may power down circuitry of the switch that handles incoming messages. The switch may be powered up from the stand-by mode by using a PHY or Layer-1 components of the switch.

Abstract: A method for the prediction, prognosis and/or diagnosis of bladder cancer or bladder cancer recurrence in a subject, the method includes: providing a test sample from the subject; measuring DNA methylation levels of at least a portion of two or more polynucleotides selected from the group consisting of HOXA9, SOXI, NPY, IRAK3, L1-MET, and Z02 in the test sample; calculating a risk score based on the measured DNA methylation levels, comparing the calculated risk score to a cut-off value derived from a reference DNA methylation profile based on DNA methylation levels of the one or more biomarkers derived from a control group, members of which had bladder cancer; and based on the comparison calculated risk score to the cut-off value, determining at least one of: (1) whether bladder cancer has recurred; (2) whether there is likelihood that the bladder cancer will recur; and (3) whether the patient has bladder cancer.

Abstract: An example method of updating firmware includes receiving a memory map of a memory. The method also includes determining, based on the memory map, a set of memory regions storing a bundle of drivers in the memory, the bundle of drivers residing in firmware and being in an executable format. The method further includes for one or more drivers in the bundle of drivers (i) building, based on the memory map, a header that describes the respective driver, and (ii) creating an object file including the header and the respective driver, where the object file is in the executable format. The method also includes storing one or more of the object files in non-volatile memory.

Abstract: A system and method are disclosed for enforcing site or organization localized provisioning policy using cryptography. In an exemplary method, a signing key is used to generate a signature for an application. The signature of the application is verified using a verifying key in order to determine whether the application adheres to the site or organization localized provisioning policy. The verifying may be performed during initialization of a computing device or during runtime of an operating system at the computing device.

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: A system and method are disclosed for enforcing site or organization localized provisioning policy using cryptography. In an exemplary method, a signing key is used to generate a signature for an application. The signature of the application is verified using a verifying key in order to determine whether the application adheres to the site or organization localized provisioning policy. The verifying may be performed during initialization of a computing device or during runtime of an operating system at the computing device.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.